Integer Holdings Corporation — Third Quarter 2026 Earnings Summary

Financial Performance:

• Total sales decreased 3.9% year-over-year to $450 million for the three months ended October 2, 2026; organic sales decreased 2.2%.
• GAAP operating income from continuing operations was $28 million, a 50% decrease from the prior year period.
• Non-GAAP adjusted operating income was $66 million, a 23% decrease year-over-year.
• GAAP income from continuing operations was $15 million, a 62% decrease year-over-year.
• Non-GAAP adjusted net income was $46 million, a 27% decrease year-over-year.
• GAAP diluted EPS from continuing operations was $0.43, a 61% decrease year-over-year.
• Non-GAAP adjusted EPS was $1.34, a 25% decrease year-over-year.
• Adjusted EBITDA totaled $88 million, a 17% decrease year-over-year.
• Total debt increased $34 million to $1.219 billion from the end of 2025.
• Non-GAAP net total debt increased $33 million to $1.223 billion.
• The leverage ratio was 3.3 times adjusted EBITDA as of October 2, 2026.
• For the nine months ended October 2, 2026, total sales were $1.35 billion, a 2.0% decrease year-over-year.
• Nine-month GAAP operating income was $94.6 million, a 42.8% decrease year-over-year.
• Nine-month non-GAAP adjusted operating income was $200.3 million, a 15.9% decrease year-over-year.
• Nine-month non-GAAP adjusted net income was $142.1 million, a 13.3% decrease year-over-year.
• Nine-month adjusted EBITDA was $267.9 million, a 9.6% decrease year-over-year.
• Cash and cash equivalents were $14.1 million as of October 2, 2026, down from $17.2 million at December 31, 2025.
• Net cash provided by operating activities for the nine months ended October 2, 2026, was $121.1 million.
• Net cash used in investing activities for the nine months ended October 2, 2026, was $81.1 million.
• Net cash used in financing activities for the nine months ended October 2, 2026, was $42.2 million.

Guidance and Future Outlook:

• The company is not providing a financial outlook due to its pending acquisition by an affiliate of investment funds managed by KKR.
• The company will not host a conference call to discuss third quarter 2026 financial results.
• The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of remaining customary closing conditions, including regulatory approvals.

Business Segments and Product Lines:

• Cardio & Vascular sales decreased 5% to $263 million in the third quarter 2026, reflecting the impact from two new Electrophysiology products.
• Cardiac Rhythm Management & Neuromodulation sales increased 4% to $176 million in the third quarter 2026, partially offset by the impact from one new Neuromodulation product.
• Other Markets sales totaled $11 million in the third quarter 2026, compared to $21 million in the prior year period, primarily due to the Portable Medical exit.
• Nine-month Cardio & Vascular sales decreased 2.2% to $805 million.
• Nine-month Cardiac Rhythm Management & Neuromodulation sales increased 3.3% to $518 million.
• Nine-month Other Markets sales decreased 46.8% to $30.4 million.

Other Key Points:

• Integer Holdings Corporation is the subject of a pending acquisition by an affiliate of investment funds managed by KKR pursuant to the Merger Agreement dated August 2, 2026.
• The Company received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act on September 29, 2026.
• Integer's stockholders approved the adoption of the Merger Agreement on October 21, 2026.
• The company recorded $50 million in repurchases of common stock during the nine months ended October 2, 2026.
• Restructuring and restructuring-related charges for the quarter included $2.2 million for a global manufacturing alignment initiative and $0.6 million for organizational realignment.
• Other adjustments included $6.9 million related to the strategic review and Transaction, $3.9 million related to a stockholder activist matter, and $1.2 million related to a cyber incident for the nine-month period.
• The company incurred $0.7 million in legal expenses related to the defense of a securities class action lawsuit during the quarter.